▲ Peaking
Business
🔮 fades
FDA approves Otsuka’s ADHD drug Simtriyo, teeing up its ‘next major CNS launch’
The FDA has approved Otsuka's new ADHD medication Simtriyo, introducing a triple reuptake inhibitor to the central nervous system market.